Turning Point Therapeutics (Nasdaq:TPTX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TPTX Overzicht aandelen

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer.

Over het bedrijf

TPTX fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 73.92% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen zinvolle omzet ( $1M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Turning Point Therapeutics, Inc. Concurrenten

Apellis Pharmaceuticals

NasdaqGS:APLS

US$3.4b

ADMA Biologics

NasdaqGM:ADMA

US$4.6b

Chinook Therapeutics

NasdaqGS:KDNY

US$2.9b

Alpine Immune Sciences

NasdaqGM:ALPN

US$4.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Turning Point Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$76.01
52 Week Hoogtepunt	US$82.20
52 Week Laag	US$23.77
Bèta	-0.19
11 maand verandering	1.58%
3 maanden verandering	114.96%
1 Jaar Verandering	18.90%
33 jaar verandering	45.39%
5 jaar verandering	n/a
Verandering sinds IPO	163.01%

Recent nieuws en updates

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

Rendement voor aandeelhouders

	TPTX	US Biotechs	US Markt
7D	1.3%	-0.5%	0.3%
1Y	18.9%	18.0%	32.4%

Rendement versus industrie: TPTX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 21.7 % opleverde.

Rendement versus markt: TPTX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 33.4 %.

Prijsvolatiliteit

Is TPTX's price volatile compared to industry and market?
TPTX volatility
TPTX Average Weekly Movement	34.2%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van TPTX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van TPTX is het afgelopen jaar gestegen van 20% naar 34%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	267	Athena Countouriotis	www.tptherapeutics.com

Turning Point Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Turning Point Therapeutics zich tot de beurswaarde?
TPTX fundamentele statistieken
Marktkapitalisatie	US$3.81b
Inkomsten(TTM)	-US$342.31m
Inkomsten(TTM)	US$1.01m

3,776x

P/S-verhouding

-11.1x

Koers/Winstverhouding

Is TPTX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TPTX resultatenrekening (TTM)
Inkomsten	US$1.01m
Kosten van inkomsten	US$0
Brutowinst	US$1.01m
Overige uitgaven	US$343.32m
Inkomsten	-US$342.31m

Laatst gerapporteerde inkomsten

Jun 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-6.84
Brutomarge	100.00%
Nettowinstmarge	-33,959.03%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde TPTX op de lange termijn?

Bekijk historische prestaties en vergelijking

TPTX Overzicht aandelen

Beloningen

Risicoanalyse

Turning Point Therapeutics, Inc. Concurrenten

NasdaqGS:APLS

US$3.4b

NasdaqGM:ADMA

US$4.6b

NasdaqGS:KDNY

US$2.9b

NasdaqGM:ALPN

US$4.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index

Turning Point Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

Turning Point Therapeutics, Inc. Provides Operational and Clinical Update

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Executive VP & CFO recently sold US$89k worth of stock

Recent updates

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index

Turning Point Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

Turning Point Therapeutics, Inc. Provides Operational and Clinical Update

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Executive VP & CFO recently sold US$89k worth of stock

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Biotechnology Index

Price target decreased to US$79.50

Price target decreased to US$87.71

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Turning Point Therapeutics, Inc. (NasdaqGS:TPTX) for $3.8 billion.

Consensus forecasts updated

Turning Point Therapeutics, Inc. Announces Appointment of Steve Sabus as Chief Commercial Officer, Effective as of May 31, 2022

Price target decreased to US$105

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

Turning Point Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Turning Point Therapeutics, Inc. Announces Positive Topline Results from the Registrational TRIDENT-1 Study Across All Four ROS1-Positive Advanced Non-Small Cell Lung Cancer Cohort

Turning Point Therapeutics, Inc. Appoints Brian Sun as Senior Vice President and General Counsel, Effective April 11, 2022

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Turning Point Therapeutics, Inc. Announces the Resignation of Siegfried Reich as Executive Vice President and Chief Scientific Officer

Full year 2021 earnings: EPS exceeds analyst expectations

Price target decreased to US$119

Turning Point Therapeutics, Inc. Announces Retirement of Annette North as Executive Vice President, General Counsel and Corporate Secretary, Effective March 4, 2022

President recently sold US$108k worth of stock

Turning Point Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for Combination of Elzovantinib and Aumolertinib in Egfr Mutant Met-Amplified Non-Small Cell Lung Cancer

Turning Point Therapeutics, Inc. Provides Updates and Anticipates 2022 Clinical and Discovery Pipeline Milestones

Turning Point Therapeutics, Inc. Announces Regulatory Updates for Its Lead Drug Candidate, Repotrectinib, ROS1/TRK Inhibitor, and for Elzovantinib (TPX-0022), Its Drug Candidate Targeting MET, CSF1R and SRC

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Price target decreased to US$134

Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference

Executive VP exercised options and sold US$630k worth of stock

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

Consensus revenue estimates increase to US$30.4m

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Executive VP & Chief Commercial Officer recently sold US$140k worth of stock

Chairman of the Board recently bought US$163k worth of stock

Turning Point Therapeutics, Inc. Grants FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Executive VP exercised options and sold US$900k worth of stock

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Senior VP of Finance & Administration and Principal Accounting Officer has left the company

Consensus forecasts updated

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Turning Point Therapeutics, Inc. Appoints Brian Baker as the Interim Principal Financial Officer

Turning Point Therapeutics, Inc. Announces Executive Changes, Effective March 31, 2021

Analysts update estimates

New 90-day low: US$103

Earnings beat expectations, revenue disappoints

Turning Point Therapeutics, Inc. Provides Operational and Clinical Updates

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

President exercised options and sold US$8.1m worth of stock

New 90-day high: US$140

Price target raised to US$160

Turning Point Therapeutics Reports Updated Interim Data from Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher